Literature DB >> 16518829

Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.

Yasuko Tsunetsugu-Yokota1, Kazuo Ohnishi, Toshitada Takemori.   

Abstract

SARS-CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS). On the occasion of the SARS outbreak, various monoclonal antibodies (mAbs) against SARS-CoV have been developed and applied for diagnosis, clinical management and basic research. In this review, we overview the biochemical and functional properties and applications of these SARS-CoV mAbs. We also focus on a variety of vaccines currently under development and discuss the immune response elicited by these vaccines in animal models, hopefully to better understand what we need to do next to fight against newly emerging pathogens in the future. 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518829      PMCID: PMC7169118          DOI: 10.1002/rmv.492

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  81 in total

1.  B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein.

Authors:  Xiaofen Zhong; Huanghao Yang; Zu-Feng Guo; Wan-Yee Fion Sin; Wei Chen; Junjie Xu; Ling Fu; Jie Wu; Chun-Kit Gannon Mak; Chak-Sum Samuel Cheng; Yanzhen Yang; Shuyong Cao; Tin-Yau Wong; Sik-To Lai; Yong Xie; Zhihong Guo
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats.

Authors:  Susanna K P Lau; Patrick C Y Woo; Kenneth S M Li; Yi Huang; Hoi-Wah Tsoi; Beatrice H L Wong; Samson S Y Wong; Suet-Yi Leung; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-16       Impact factor: 11.205

3.  Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies.

Authors:  Kazuo Ohnishi; Masahiro Sakaguchi; Tomohiro Kaji; Kiyoko Akagawa; Tadayoshi Taniyama; Masataka Kasai; Yasuko Tsunetsugu-Yokota; Masamichi Oshima; Kiichi Yamamoto; Naomi Takasuka; Shu-ichi Hashimoto; Manabu Ato; Hideki Fujii; Yoshimasa Takahashi; Shigeru Morikawa; Koji Ishii; Tetsutaro Sata; Hirotaka Takagi; Shigeyuki Itamura; Takato Odagiri; Tatsuo Miyamura; Ichiro Kurane; Masato Tashiro; Takeshi Kurata; Hiroshi Yoshikura; Toshitada Takemori
Journal:  Jpn J Infect Dis       Date:  2005-04       Impact factor: 1.362

4.  Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients.

Authors:  Xuan Liu; Yulin Shi; Ping Li; Linhai Li; Yanping Yi; Qingjun Ma; Cheng Cao
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

Review 5.  The molecular biology of coronaviruses.

Authors:  M M Lai; D Cavanagh
Journal:  Adv Virus Res       Date:  1997       Impact factor: 9.937

Review 6.  Severe acute respiratory syndrome.

Authors:  J S M Peiris; Y Guan; K Y Yuen
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

7.  Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus.

Authors:  Michael J Gubbins; Frank A Plummer; Xin Y Yuan; Darrell Johnstone; Mike Drebot; Maya Andonova; Anton Andonov; Jody D Berry
Journal:  Mol Immunol       Date:  2005-01       Impact factor: 4.407

8.  SARS corona virus peptides recognized by antibodies in the sera of convalescent cases.

Authors:  Jian-Ping Guo; Martin Petric; William Campbell; Patrick L McGeer
Journal:  Virology       Date:  2004-07-01       Impact factor: 3.616

9.  Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection.

Authors:  Wai K Leung; Ka-Fai To; Paul K S Chan; Henry L Y Chan; Alan K L Wu; Nelson Lee; Kwok Y Yuen; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

10.  Human aminopeptidase N is a receptor for human coronavirus 229E.

Authors:  C L Yeager; R A Ashmun; R K Williams; C B Cardellichio; L H Shapiro; A T Look; K V Holmes
Journal:  Nature       Date:  1992-06-04       Impact factor: 49.962

View more
  15 in total

1.  The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.

Authors:  Tatiana Baranovich; Jeremy C Jones; Marion Russier; Peter Vogel; Kristy J Szretter; Susan E Sloan; Patrick Seiler; Jose M Trevejo; Richard J Webby; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 2.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

Review 3.  Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.

Authors:  Yuhang Wang; Matthew Grunewald; Stanley Perlman
Journal:  Methods Mol Biol       Date:  2020

4.  Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.

Authors:  Masahiro Ikejiri; Masayuki Saijo; Shigeru Morikawa; Shuetsu Fukushi; Tetsuya Mizutani; Ichiro Kurane; Tokumi Maruyama
Journal:  Bioorg Med Chem Lett       Date:  2007-02-13       Impact factor: 2.823

5.  Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.

Authors:  Oi-Wing Ng; Choong-Tat Keng; Cynthia Sau-Wai Leung; J S Malik Peiris; Leo Lit Man Poon; Yee-Joo Tan
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

6.  Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.

Authors:  Chi-Yuan Chou; Chia-Hui Chien; Yu-San Han; Mojca Trstenjak Prebanda; Hsing-Pang Hsieh; Boris Turk; Gu-Gang Chang; Xin Chen
Journal:  Biochem Pharmacol       Date:  2008-01-19       Impact factor: 5.858

7.  Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen.

Authors:  Yasuko Tsunetsugu-Yokota
Journal:  Methods Mol Biol       Date:  2008

8.  A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.

Authors:  Yu-ya Mitsuki; Kazuo Ohnishi; Hirotaka Takagi; Masamichi Oshima; Takuya Yamamoto; Fuminori Mizukoshi; Kazutaka Terahara; Kazuo Kobayashi; Naoki Yamamoto; Shoji Yamaoka; Yasuko Tsunetsugu-Yokota
Journal:  Microbes Infect       Date:  2008-06-19       Impact factor: 2.700

9.  A fluorogenic peptide containing the processing site of human SARS corona virus S-protein: kinetic evaluation and NMR structure elucidation.

Authors:  Ajoy Basak; Abhijit Mitra; Sarmistha Basak; Carolyn Pasko; Michel Chrétien; Pamela Seaton
Journal:  Chembiochem       Date:  2007-06-18       Impact factor: 3.164

10.  SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.

Authors:  Yunfei Wang; Lichun Wang; Han Cao; Cunbao Liu
Journal:  J Med Virol       Date:  2020-10-05       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.